Prolia denosumab: Extension study data

An open-label extension of a 2-year Phase II trial in 200 patients showed that BMD at the lumbar spine and total hip in patients who received Prolia for 8 years (n=80) increased by an average of 16.8% and 6.9%, respectively, from baseline of the parent study and by 5.8% and 2%, respectively, from baseline of the extension study. Amgen also said that reductions in 2 biomarkers of bone turnover - C-terminal telopeptide of type I collagen (CTX-I) and bone-specific alkaline phosphatase (b-ALP) - were sustained over 8 years of treatment with Prolia. Data were presented at the American Society for Bone and Mineral Research meeting in San Diego. ...